Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Palbociclib (Ibrance)

Notes:

Quantity Limits: Yes

<u>Initiation (new start) criteria</u>: Formulary palbociclib (Ibrance) will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by a hematologist or oncologist
- Age greater than or equal to 18 years
- Patient has diagnosis of hormone-positive, HER2-negative, advanced, or metastatic breast cancer and meets the following:
 - No disease progression while on ribociclib (Kisqali) OR abemaciclib (Verzenio) – AND –
 - Adequate trial of ribociclib 200 to 400 mg dose with documented toxicity
 OR –
 - o Relative contraindication to ribociclib defined as any of the following:
 - Long QT syndrome
 - Baseline QTc greater than or equal to 450 ms
 - Use of drugs that are known to prolong the QT interval
 - Use of tamoxifen
 - Use of strong CYP3A4 inhibitors
 - Uncontrolled or significant cardiac disease (such as myocardial infarction or arrhythmias within the past 12 months, congestive heart failure NYHA class III-IV or with LVEF < 50%, unstable angina, or bradycardia)

<u>Criteria for current Kaiser Permanente members already taking the medication who</u>
<u>have not been reviewed previously</u>: Formulary palbociclib (Ibrance) will be covered
on the prescription drug benefit when the following criteria are met:

- Prescribed by a hematologist or oncologist
- Age greater than or equal to 18 years
- Patient has diagnosis of hormone-positive, HER2-negative, advanced, or metastatic breast cancer

kp.org

Revised: 06/08/23 Effective: 08/17/23 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest



Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

Palbociclib (Ibrance)

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Formulary palbociclib (Ibrance)
will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by a hematologist or oncologist
- Age greater than or equal to 18 years
- Patient has diagnosis of hormone-positive, HER2-negative, advanced, or metastatic breast cancer

kp.org

Revised: 06/08/23 Effective: 08/17/23



